Intellia Therapeutics, Inc. Profile Avatar - Palmy Investing

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]

News

Theses · Events · Sentiments
Sentiments
24-10-17 19.60%

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.

End of NTLA's Analysis
CIK: 1652130 CUSIP: 45826J105 ISIN: US45826J1051 LEI: - UEI: -
Secondary Listings
NTLA has no secondary listings inside our databases.